Logically, the administration of a mouse anti-IL10 monoclonal antibody (aiming at the neutralization of IL10) has shown beneficial outcomes in SLE patients in a small-sized pioneering clinical trial [10]. The gene discussed is IL10; the disease is systemic lupus erythematosus.